Viewing Study NCT06048250


Ignite Creation Date: 2025-12-24 @ 4:56 PM
Ignite Modification Date: 2026-01-25 @ 6:15 AM
Study NCT ID: NCT06048250
Status: RECRUITING
Last Update Posted: 2025-05-01
First Post: 2023-09-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Sponsor: City of Hope Medical Center
Organization:

Organization Data

Organization:
Class: OTHER
Study ID: 22143
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None NIH View